MA30440B1 - NOUVEAUX MEDICAMENTS ANTIARYTHMIQUES ET CONTRE LA DEFAILLANCE CARDIAQUE CIBLANT LA FUITE DANS UN RECEPTEUR DE LA PYANODINE (RyR2). - Google Patents

NOUVEAUX MEDICAMENTS ANTIARYTHMIQUES ET CONTRE LA DEFAILLANCE CARDIAQUE CIBLANT LA FUITE DANS UN RECEPTEUR DE LA PYANODINE (RyR2).

Info

Publication number
MA30440B1
MA30440B1 MA30288A MA30288A MA30440B1 MA 30440 B1 MA30440 B1 MA 30440B1 MA 30288 A MA30288 A MA 30288A MA 30288 A MA30288 A MA 30288A MA 30440 B1 MA30440 B1 MA 30440B1
Authority
MA
Morocco
Prior art keywords
ryr2
methods
exercise
provides
novel
Prior art date
Application number
MA30288A
Other languages
English (en)
Inventor
Andrew R Marks
Donald W Landry
Shixian Deng
Zhen Zhuang Cheng
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37024084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30440(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MA30440B1 publication Critical patent/MA30440B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention apporte de nouveaux intermédiaires et dérivés de la 1,4-benzothiazépine, et des procédés pour leur synthétisation et leur dosage. Elle fournit également des procédés d'utilisation de ces nouveaux composés pour limiter ou prévenir une diminution du taux du complexe FKBP12.6-RyR2 chez un sujet ; afin de prévenir une mort cardiaque subite lors d'un exercice physique ; de traiter ou prévenir une défaillance cardiaque, une fibrillation auriculaire ou une arythmie cardiaque produite par un exercice. La présente invention apporte en outre des procédés de détection de l'agent qui accentue la liaison du RyR2 et du FKBP12.6, et les agents détectés par ces procédés. De plus, cette invention apporte un procédé de détection des agents pour le traitement et la prévention des défaillances cardiaques, la fibrillation auriculaire ou l'arythmie produite par un exercice, et la prévention d'une mort cardiaque subitelors d'un exercice. Elle fournit également les agents identifiés par de tels procédés.
MA30288A 2005-03-23 2007-10-11 NOUVEAUX MEDICAMENTS ANTIARYTHMIQUES ET CONTRE LA DEFAILLANCE CARDIAQUE CIBLANT LA FUITE DANS UN RECEPTEUR DE LA PYANODINE (RyR2). MA30440B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/088,058 US7544678B2 (en) 2002-11-05 2005-03-23 Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)

Publications (1)

Publication Number Publication Date
MA30440B1 true MA30440B1 (fr) 2009-06-01

Family

ID=37024084

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30288A MA30440B1 (fr) 2005-03-23 2007-10-11 NOUVEAUX MEDICAMENTS ANTIARYTHMIQUES ET CONTRE LA DEFAILLANCE CARDIAQUE CIBLANT LA FUITE DANS UN RECEPTEUR DE LA PYANODINE (RyR2).

Country Status (15)

Country Link
US (2) US7544678B2 (fr)
EP (1) EP1861385A1 (fr)
JP (1) JP2008534497A (fr)
KR (1) KR20070116900A (fr)
CN (1) CN101146785A (fr)
AU (1) AU2005329398A1 (fr)
BR (1) BRPI0520160A2 (fr)
CA (1) CA2601541A1 (fr)
EA (1) EA200702057A1 (fr)
IL (1) IL185668A0 (fr)
MA (1) MA30440B1 (fr)
MX (1) MX2007011528A (fr)
NO (1) NO20075386L (fr)
WO (1) WO2006101496A1 (fr)
ZA (1) ZA200707573B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) * 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (ja) * 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2008021439A2 (fr) * 2006-08-17 2008-02-21 The Trustees Of Columbia University In The City Of New York Compositions et méthodes de traitement de l'hypertrophie cardiaque
WO2008140592A2 (fr) * 2006-11-29 2008-11-20 Armgo Pharma, Inc. 1,4-benzothiazépines radioactivement marquées et procédés de criblage de composés qui lient les récepteurs de la ryanodine
US8768469B2 (en) 2008-08-08 2014-07-01 Enteromedics Inc. Systems for regulation of blood pressure and heart rate
CN101812523B (zh) * 2010-04-09 2012-08-22 广州益善生物技术有限公司 Ryr1基因snp检测特异性引物、液相芯片和检测方法
WO2013064231A1 (fr) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag Sulfonamides à sept chaînons comme modulateurs des récepteurs gamma orphelins associés à un récepteur de l'acide rétinoïque (rorγ, nr1f3)
EP2708535A1 (fr) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents pour le traitement de troubles impliquant la modulation de récepteurs de la ryanodine
IL305285A (en) * 2015-08-11 2023-10-01 Arch Biopartners Inc DPEP-1 binding compositions and methods of use
US11426415B2 (en) 2017-03-06 2022-08-30 Washington University Treatment for Wolfram syndrome and other endoplasmic reticulum stress disorders
EP3837263B1 (fr) * 2018-08-13 2024-07-03 F. Hoffmann-La Roche AG Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
EP3883936B1 (fr) 2018-11-22 2023-07-12 F. Hoffmann-La Roche AG Nouveaux composés hétérocycliques
TWI827866B (zh) * 2019-07-22 2024-01-01 日商埃塔斯製藥股份有限公司 有光學活性的1,4-苯並硫氮呯-1-氧化物衍生物的製造方法
CN114105916B (zh) * 2021-11-25 2023-04-18 深圳大学 一种RyR2稳定剂及其制备方法、相应的药用组合物和应用

Family Cites Families (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060786A (en) * 1963-10-09 1967-03-08 Wander Ag Dr A Process for the preparation of lactams
US3519647A (en) 1966-10-12 1970-07-07 Squibb & Sons Inc 2,3,4,5-tetrahydro-1,5-benzothiazepines
EP0150996B1 (fr) * 1984-01-27 1988-01-07 Ajinomoto Co., Inc. Préparation des dérivés d'acide heptanoique
EP0238700B1 (fr) 1986-03-27 1991-01-23 Topy Industries, Limited Catalyseur d'oxydation du monoxyde de carbone
US4567254A (en) * 1984-09-19 1986-01-28 Kikkoman Corporation Method for preparing N6,8-disubstituted 3',5'-cyclic adenosine monophosphate and salt thereof
US4849535A (en) 1985-02-26 1989-07-18 Ajinomoto Co., Inc. Production of cyclopentenylheptanoic acid derivatives
US4841055A (en) * 1985-03-25 1989-06-20 Japan Tobacco Inc. Desmosine derivatives and reagent for preparing artificial antigens
US4723012A (en) * 1985-03-25 1988-02-02 Japan Tobacco Inc. Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same
US6956032B1 (en) * 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
JPS63227599A (ja) 1987-03-14 1988-09-21 Kirin Brewery Co Ltd アンスラサイクリン化合物およびその用途
US5179125A (en) * 1987-12-03 1993-01-12 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
US5210266A (en) * 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
EP0368063B1 (fr) * 1988-11-05 1992-06-10 Bayer Ag Procédé pour la chlorination dans le noyau d'hydrocarbures aromatiques
US5272164A (en) 1988-12-27 1993-12-21 Kirin Beer Kabushiki Kaisha Carboximidamide derivatives
US5223508A (en) * 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
JPH0662567B2 (ja) 1988-12-27 1994-08-17 麒麟麦酒株式会社 ピリジンカルボキシイミダミド誘導体、その製造中間体、製造法および用途
US5142647A (en) 1989-04-18 1992-08-25 Japan Tobacco, Inc. Magnus measuring apparatus
WO1991004654A1 (fr) 1989-09-30 1991-04-18 Kirin Beer Kabushiki Kaisha Procede de production de plants
US5075293A (en) 1989-10-10 1991-12-24 The Dow Chemical Company ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
US5153184A (en) 1989-10-10 1992-10-06 Dowelanco ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
KR940000166B1 (ko) * 1989-11-09 1994-01-08 니혼다바고 상교오 가부시기가이샤 신규 글루코사민 유도체 및 이것을 막 구성성분으로서 함유한 리포솜
US4963671A (en) 1989-11-20 1990-10-16 E. R. Squibb & Sons, Inc. Process for resolving chiral intermediates used in making calcium channel blockers
CA2047226A1 (fr) * 1989-12-27 1991-06-28 Jun-Ichi Haruta Oxyde de 1,3,2-dioxathiolane
KR920701200A (ko) * 1990-03-30 1992-08-11 미즈노 시게루 신규의 4h-3,1-벤조옥사진-4-온 유도체
WO1992018488A1 (fr) 1991-04-10 1992-10-29 Japan Tobacco Inc. Nouveau derive d'oxazinone
JP2651043B2 (ja) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
US5082847A (en) 1990-07-18 1992-01-21 Syntex (U.S.A.) Inc. Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility
US5064810A (en) 1990-09-14 1991-11-12 Jeffrey Askanazi Use of branched chain amino acids to effect diaphragm contractility and fatigue
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
DE4102103A1 (de) * 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DK0694545T3 (da) 1991-05-03 2000-09-18 Searle & Co Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
US5182272A (en) * 1991-05-03 1993-01-26 G. D. Searle & Co. 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
DE69229333D1 (de) 1991-07-04 1999-07-08 Japan Tobacco Inc Verfahren zur kultivierung von vorläufer t-zellinien
US5593988A (en) * 1991-10-11 1997-01-14 Yoshitomi Pharmaceutical Industries, Ltd. Therapeutic agent for osteoporosis and diazepine compound
CA2080428C (fr) * 1991-10-22 2004-01-27 Ray F. Ebert Methode de preparation d'un reactif de la thromboplastine a partir d'une culture cellulaire, pouvant servir a mesurer le temps de prothrombine
AU3143593A (en) 1991-12-20 1993-07-28 G.D. Searle & Co. Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin E2 antagonists
MX9300433A (es) * 1992-01-28 1994-07-29 Kirin Brewery Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen.
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
JP2667351B2 (ja) 1992-03-24 1997-10-27 麒麟麦酒株式会社 食餌脂質消化吸収阻害剤および飲食品
US5387684A (en) * 1992-03-25 1995-02-07 The Green Cross Corporation Isoindazole compound
JP3093419B2 (ja) 1992-03-30 2000-10-03 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
US5304644A (en) * 1992-04-15 1994-04-19 G. D. Searle & Co. 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
WO1994001409A1 (fr) 1992-07-02 1994-01-20 Fujisawa Pharmaceutical Co., Ltd. Nouvel intermediaire pour la synthese et la production d'un derive d'aminoacide
WO1994004523A1 (fr) * 1992-08-21 1994-03-03 Japan Tobacco Inc. Compose dioxacycloalcane a activite inhibitrice de la renine
US5260286A (en) 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
RU2115650C1 (ru) 1992-11-09 1998-07-20 Дзе Бутс Компани ПЛС 2,3,4,5-тетрагидро-1,4-бензотиазепины, их стереоизомеры или их фармацевтически приемлемые соли, способ их получения, фармацевтическая композиция, обладающая противосудорожным действием
US5354758A (en) 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
CA2160566C (fr) 1993-04-15 2004-07-13 Tatsuo Higa Nouveaux sphingoglycolipides et leurs utilisations
US5461047A (en) 1993-06-16 1995-10-24 G. D. Searle & Co. 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5354747A (en) 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
JP3437577B2 (ja) 1993-08-19 2003-08-18 日本たばこ産業株式会社 植物由来のａｔｐ依存フルクトース６リン酸１ホスホトランスフェラーゼをコードするｄｎａ，それを含む組換えベクター及びそれを用いる低温下で植物細胞中の糖含量を変化させる方法
FR2709753B1 (fr) 1993-09-09 1995-12-01 Hoechst Lab Nitrates organiques, leur procédé de préparation et leur application comme médicaments.
WO1995013272A1 (fr) * 1993-11-10 1995-05-18 Japan Tobacco Inc. Derive de chromanne et utilisation therapeutique de ce dernier
US6897295B1 (en) * 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JP2706755B2 (ja) * 1994-02-10 1998-01-28 日本たばこ産業株式会社 新規なベンジルアミノエトキシベンゼン誘導体
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5449675A (en) 1994-06-09 1995-09-12 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine urea compounds, pharmaceutical compositions and methods of use
EP0764720B1 (fr) * 1994-06-15 2005-12-14 Kirin Beer Kabushiki Kaisha Transferase et amylase, procede de production de ces enzymes, utilisation, et genes les codant
US20040175814A1 (en) 1994-06-15 2004-09-09 Kirin Beer Kubushiki Kaisha Novel transferase and amylase, process for producing the enzymes, use thereof, and gene coding for the same
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
IT1271007B (it) 1994-09-13 1997-05-26 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidronaftalene attivi sul sistema cardiovascolare
EP0741144B1 (fr) 1994-11-11 2002-07-24 Noboru Kaneko Anticorps monoclonal antiannexine-v, procede pour produire cet anticorps, et utilisation de cet anticorps
AU694278B2 (en) 1994-11-18 1998-07-16 Japan Tobacco Inc. Osteoporosis remedy and triazepine compound
AU6470096A (en) 1995-07-19 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused triazole compounds
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US6660837B1 (en) 1995-09-14 2003-12-09 Kirin Beer Kabushiki Kaisha Modified protein derived from protein kinase N
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
TW458978B (en) 1995-11-07 2001-10-11 Astra Ab Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
ES2364179T3 (es) * 1996-07-08 2011-08-26 Kyowa Hakko Kirin Co., Ltd. Compuestos con actividad receptora de calcio.
JP3861187B2 (ja) 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
GB9616279D0 (en) 1996-08-02 1996-09-11 Knoll Ag Chemical process
US6111072A (en) 1996-08-26 2000-08-29 Kirin Beer Kabushiki Kaisha Rho target protein human mDia and gene encoding same
US6338955B2 (en) * 1996-12-12 2002-01-15 Kirin Beer Kabushiki Kaisha β1-4 N-acetylglucosaminyltransferase and gene encoding
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6011036A (en) 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
DE19722317C1 (de) 1997-05-28 1998-10-08 Boehringer Ingelheim Int Das Protein des humanen Ryanodinrezeptors vom Typ 3 sowie dafür kodierende DNA-Moleküle
AUPO941497A0 (en) 1997-09-24 1997-10-16 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
JP4431798B2 (ja) 1997-10-08 2010-03-17 昇 金子 尿中のアネキシンｖの分析方法及びその利用
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
EP1034164B1 (fr) 1997-11-24 2004-05-19 Merck & Co., Inc. Derives d'alanine-beta agissant en tant qu'inhibiteurs de l'adhesion cellulaire
GB9724813D0 (en) 1997-11-25 1998-01-21 Univ Nottingham Reducing muscle fatigue
AU7109798A (en) 1997-12-02 1998-10-30 Dr. Reddy's Research Foundation Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypol ipidemia and antihypertensive properties
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
WO1999032115A1 (fr) 1997-12-19 1999-07-01 Advanced Research And Technology Institute, Inc. Modulateurs des recepteurs de la ryanodine contenant des 2-(aryl)-4,7-dioxobenzothiazoles et leurs analogues
EP1043335A4 (fr) 1997-12-25 2005-08-31 Japan Tobacco Inc Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales
JP3865096B2 (ja) 1998-01-09 2007-01-10 宇部興産株式会社 ジベンゾチアゼピン誘導体の製造方法
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
TR200003598T2 (tr) 1998-03-26 2001-06-21 Japan Tobacco Inc. Amid türevleri ve nosiseptin antagonistleri
SK15072000A3 (sk) * 1998-04-10 2001-08-06 Japan Tobacco Inc. Amidové zlúčeniny
CA2319142A1 (fr) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Agents therapeutiques agissant sur les transporteurs membranaires
US6890531B1 (en) * 1998-07-31 2005-05-10 Kirin Beer Kabushiki Kaisha Neuronal growth factor galectin-1
WO2000016806A1 (fr) 1998-09-17 2000-03-30 Nippon Kayaku Kabushiki Kaisha Remedes pour photochimioterapie
EP1147772B1 (fr) 1998-12-28 2006-01-04 Noboru Kaneko utilisation de derivées 1,4-benzothiazepines pour la preparation d'un medicament dans LE TRAITEMENT DE LA FIBRILLATION atriale
DK1167537T3 (da) * 1999-03-30 2008-11-10 Japan Tobacco Inc Fremgangsmåde til fremstilling af et monoklonalt antistof
EP1184037B1 (fr) 1999-05-19 2005-06-29 Noboru Kaneko Utilisation de derives 1,4-benzothiazepine en tant que medicaments contre la tolerance cancerostatique
GB9914745D0 (en) 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
ATE359788T1 (de) * 1999-09-30 2007-05-15 Noboru Kaneko Verwendung von diphenylmethylpiperazin-derivaten zur herstellung eines medikaments zur unterdrückung der proliferation von fibroblasten
TWI281915B (en) 1999-12-24 2007-06-01 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
WO2001047510A2 (fr) 1999-12-29 2001-07-05 Glaxo Group Limited Methodes et compositions liees aux modulateurs de l'annexine et de l'homeostasie cartilagineuse
ATE291737T1 (de) 2000-01-14 2005-04-15 Migenix Corp Screening-assays unter verwendung von intramitochondrialem kalzium
ATE362926T1 (de) * 2000-01-20 2007-06-15 Eisai R&D Man Co Ltd Stickstoffhaltige cyclische verbindungen und sie enthaltende pharmazeutische zubereitungen
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
ATE420878T1 (de) 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
DK1265859T3 (da) 2000-03-24 2006-05-01 Pharmacia Corp Amidinoforbindelser der er nyttige som nitrogenoxidsyntaseinhibitorer
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
US6787668B2 (en) 2000-04-13 2004-09-07 Pharmacia Corporation 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
US6545170B2 (en) * 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20060293266A1 (en) 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US6489125B1 (en) 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20040229781A1 (en) 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20030220312A1 (en) 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
AU2001261434A1 (en) 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
US20020042405A1 (en) * 2000-07-27 2002-04-11 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
RU2262511C2 (ru) 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
EP1300142A4 (fr) 2000-07-05 2004-05-19 Ajinomoto Kk Composes hypoglycemiques
WO2002002517A1 (fr) 2000-07-05 2002-01-10 Ajinomoto Co.,Inc. Derives d'acylsulfonamides
EA005817B1 (ru) 2000-08-01 2005-06-30 Фармасиа Корпорейшн Производные гексагидро-7-1h-азепин-2-илгексановой (или гексеновой) кислоты в качестве ингибиторов индуцибельной синтазы оксида азота
DE10039717A1 (de) 2000-08-14 2002-02-28 Bayer Ag Verfahren zur Kernchlorierung von meta-Xylol
DE10039722A1 (de) 2000-08-14 2002-02-28 Bayer Ag Verfahren zur Kernchlorierung von ortho-Xylol
WO2003034980A2 (fr) 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. Nouveau compose pharmaceutique contenant du sulfate d'abacavir et procedes de fabrication et d'utilisation associes
AR031608A1 (es) 2000-09-15 2003-09-24 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-3-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
AR030741A1 (es) * 2000-09-15 2003-09-03 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa
US6936426B2 (en) * 2000-10-06 2005-08-30 Harbor-Ucla Research And Education Institute Detection of antibody mediated inflammatory auto-immune disorders
JP3523245B1 (ja) * 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
EP1355588B1 (fr) 2000-12-22 2007-08-15 Avantec Vascular Corporation Dispositif d'administration des agents therapeutiques
US6673904B2 (en) * 2000-12-23 2004-01-06 Kirin Beer Kabushiki Kaisha Stem cell growth factor-like polypeptides
WO2002051232A2 (fr) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Nouvelles benzazepines et derives heterocycliques associes
WO2002053548A1 (fr) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Derives de la benzothiazepine
US6962926B2 (en) 2001-01-31 2005-11-08 Telik, Inc. Antagonist of MCP-1 function, and compositions and methods of use thereof
US20050074762A1 (en) * 2001-02-01 2005-04-07 Yusuke Nakamura Adiponectin-associated protein
JP4817514B2 (ja) 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
EP1369129A4 (fr) 2001-03-14 2005-08-03 Ono Pharmaceutical Co Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
AU2002306868A1 (en) 2001-03-28 2002-10-15 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
AU2002255284B2 (en) * 2001-04-27 2007-10-04 Kyowa Kirin Co., Ltd. Quinoline derivative having azolyl group and quinazoline derivative
JP4230681B2 (ja) 2001-07-06 2009-02-25 株式会社東芝 高耐圧半導体装置
US20030220310A1 (en) 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6869975B2 (en) * 2001-09-14 2005-03-22 Tularik Inc. Linked biaryl compounds
JP4087338B2 (ja) 2001-11-15 2008-05-21 キリンファーマ株式会社 キメラ非ヒト動物
JP2003145746A (ja) * 2001-11-16 2003-05-21 Seiko Epson Corp インクジェット記録方法及びインクジェット記録装置
WO2003043655A1 (fr) 2001-11-19 2003-05-30 Ono Pharmaceutical Co., Ltd. Remedes pour la frequence urinaire
AU2002349705A1 (en) * 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
US20040171613A1 (en) 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
WO2003061699A1 (fr) 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedes pour affections allergiques
BR0306643A (pt) * 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
WO2003064404A1 (fr) 2002-02-01 2003-08-07 Dainippon Pharmaceutical Co., Ltd. Hydrazides d'acide 2-furancarboxylique et compositions pharmaceutiques les contenant
AU2003211997B2 (en) 2002-02-14 2009-01-29 Kirin Beer Kabushiki Kaisha Compositions and foods for improving lipid metabolism
JPWO2003090570A1 (ja) * 2002-04-26 2005-08-25 日本たばこ産業株式会社 棒状物品の成形装置
US7439332B2 (en) 2002-04-26 2008-10-21 Kirin Pharma Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem or progenitor cells
JP4113042B2 (ja) * 2002-05-24 2008-07-02 シチズンホールディングス株式会社 表示装置およびカラー表示方法
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
ES2277142T3 (es) * 2002-08-30 2007-07-01 Japan Tobacco Inc. Compuesto de dibencilamina y su uso medicinal.
JP2004103256A (ja) 2002-09-04 2004-04-02 Nippon Chemicon Corp 非常灯
CA2502583A1 (fr) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha Derives d'isoquinoline d'inhibition des kinases et medicaments contenant ceux-ci
KR20050062551A (ko) 2002-09-20 2005-06-23 기린 비루 가부시키가이샤 α-글리코실세라미드를 유효 성분으로 하는 Ｃ형 간염 바이러스 억제제
WO2004031385A1 (fr) 2002-10-04 2004-04-15 Kirin Beer Kabushiki Kaisha Vecteur de chromosome humain artificiel (hac)
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2004042389A2 (fr) 2002-11-08 2004-05-21 Bayer Healthcare Ag Moyens diagnostiques et therapeutiques destines a des maladies associees a la phosphodiesterase 4d (pde4d) humaine
AU2003293006A1 (en) 2002-11-22 2004-06-18 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
EP1439221B1 (fr) 2002-12-17 2007-01-24 F. Hoffmann-La Roche Ag Construction dérivée du noyau de PDE
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
TWI220798B (en) 2003-03-07 2004-09-01 Hitachi Cable Light-emitting diode array
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
CA2519458A1 (fr) 2003-03-17 2004-09-30 Japan Tobacco Inc. Procede pour accroitre la biodisponibilite orale de s- 2-( '1-(2-ethylbutyl)cyclohexyl!carbonyl!amino)phenyl!-2-methylpropanethioate
PL1603553T3 (pl) 2003-03-17 2012-04-30 Japan Tobacco Inc Kompozycje farmaceutyczne inhibitorów CETP
CL2004000544A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
US20040235162A1 (en) 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
EP1614676A4 (fr) 2003-03-27 2009-03-25 Kirin Pharma Kk Compose inhibiteur in vivo de transport de phosphore et medicament en contenant
WO2004089918A1 (fr) 2003-04-09 2004-10-21 Japan Tobacco Inc. Compose pentacyclique heteroaromatique et son usage medical
WO2004093816A2 (fr) 2003-04-22 2004-11-04 Pharmacia Corporation Compositions renfermant un inhibiteur selectif de cyclo-oxygenase-2 et un agent modulateur de calcium pour le traitement de dommages au systeme nerveux central
WO2004093896A1 (fr) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions constituees d'un inhibiteur selectif de la cyclooxygenase-2 et d'un modulateur des canaux ioniques du potassium destinees au traitement de lesions du systeme nerveux central
WO2004093813A2 (fr) 2003-04-22 2004-11-04 Pharmacia Corporation Compositions renfermant un inhibiteur selectif a l'egard de la cyclooxygenase 2 et un agent de modulation du calcium pour le traitement de la douleur, de l'inflammation ou de troubles dus a l'inflammation
US20040229803A1 (en) 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US20050070543A1 (en) * 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
EP1653969A4 (fr) * 2003-08-07 2006-12-20 Japan Tobacco Inc Derives de pyrrolo 1,2-b pyridazine
CA2536173A1 (fr) * 2003-08-20 2005-03-03 Nitromed, Inc. Composes cardiovasculaires nitroses et nitrosyles, compositions et procedes d'utilisation
JP2007504135A (ja) * 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
US20050187221A1 (en) 2003-09-08 2005-08-25 Japan Tobacco Inc. Method of treating ischemia reperfusion injury
EP1703908A4 (fr) 2003-12-22 2009-07-08 Amgen Inc Composes de sulfonamide d'aryle et procedes d'utilisation correspondants
US7165879B2 (en) 2004-03-25 2007-01-23 Red Devil Equipment Company Clamp lock apparatus and method for a paint mixer
CA2563064A1 (fr) * 2004-04-22 2005-11-10 Kirin Beer Kabushiki Kaisha Animaux transgeniques et leurs utilisations
EP1743895A4 (fr) 2004-04-28 2010-06-16 Aetas Pharma Co Ltd Accélérateur du relachement des muscles et agent thérapeutique pour des maladies des tissus musculaires telles qu'une insuffisance du relâchement des muscles
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP3968358B2 (ja) 2004-06-30 2007-08-29 日本電信電話株式会社 薄型フラットツイストぺアすきまケーブル及びすきまナビゲータユニット
US8195136B2 (en) * 2004-07-15 2012-06-05 At&T Intellectual Property I, L.P. Methods of providing caller identification information and related registries and radiotelephone networks
EP1777225A4 (fr) * 2004-07-15 2009-06-24 Japan Tobacco Inc Composé benzamide fusionné et inhibiteur d'activité récepteur vanilloïde 1 (vr1)
JP2006094849A (ja) 2004-08-30 2006-04-13 Kirin Brewery Co Ltd 相同組換え効率が向上した分化多能性細胞及びその利用
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
WO2006071603A2 (fr) 2004-12-16 2006-07-06 The Trustees Of Columbia University In The City Of New York Protection de la phosphodiesterase 4d dans le complexe du recepteur de la ryanodine contre une insuffisance cardiaque
EP1855688A4 (fr) 2005-02-24 2011-09-14 Nicox Sa Compositions et composes diuretiques renforçateurs d'oxyde nitrique, et leurs procedes d'utilisation
KR100917511B1 (ko) 2005-02-28 2009-09-16 니뽄 다바코 산교 가부시키가이샤 Ｓｙｋ 저해 활성을 갖는 신규한 아미노피리딘 화합물
WO2006098394A1 (fr) 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors

Also Published As

Publication number Publication date
KR20070116900A (ko) 2007-12-11
IL185668A0 (en) 2008-01-06
JP2008534497A (ja) 2008-08-28
CN101146785A (zh) 2008-03-19
WO2006101496A1 (fr) 2006-09-28
US20100152440A1 (en) 2010-06-17
EP1861385A1 (fr) 2007-12-05
CA2601541A1 (fr) 2006-09-28
NO20075386L (no) 2007-12-14
ZA200707573B (en) 2008-07-30
MX2007011528A (es) 2007-12-12
EA200702057A1 (ru) 2008-04-28
BRPI0520160A2 (pt) 2009-04-22
AU2005329398A1 (en) 2006-09-28
US7544678B2 (en) 2009-06-09
US20050187386A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
MA30440B1 (fr) NOUVEAUX MEDICAMENTS ANTIARYTHMIQUES ET CONTRE LA DEFAILLANCE CARDIAQUE CIBLANT LA FUITE DANS UN RECEPTEUR DE LA PYANODINE (RyR2).
MA29326B1 (fr) Combinaison de composes organiques
Grossmann et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting
Abdouh et al. Retinal plasma extravasation in streptozotocin‐diabetic rats mediated by kinin B1 and B2 receptors
Saini et al. Therapeutic potentials of sarpogrelate in cardiovascular disease
MA29810B1 (fr) 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques
Hjermitslev et al. Azilsartan medoxomil, an angiotensin II receptor antagonist for the treatment of hypertension
MA29543B1 (fr) Procedes pour traiter un cancer pharmacoresistant
TW200918525A (en) Compounds
US20090221656A1 (en) Drug Combinations
Dow et al. The evolution of small molecule enzyme activators
MA46268B1 (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
Hamai et al. Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress
SK16792001A3 (sk) Spoločné proliečivá amlodipínu a atorvastatínu
Yeates DB-289 (Immtech International)
Warnholtz et al. AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease
MA29812B1 (fr) N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques
US20180256521A1 (en) Multiple myeloma treatment
WO2004075856A3 (fr) Methode de traitement d'une maladie au moyen d'un antagoniste du recepteur de l'adenosine a1
Toto Heart disease in diabetic patients
McKenney et al. Safety of extended-release niacin/laropiprant in patients with dyslipidemia
Oparil et al. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension
P Petzer et al. Leflunomide, a reversible monoamine oxidase inhibitor
MA32128B1 (fr) Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artémisinine ou l'un de ses derives pour le traitement du paludisme severe
EP2351567A4 (fr) Composition pharmaceutique et medicament pour la prevention et le traitement de diabetes ou de l'obesite comprenant comme principe actif, un compose qui inhibe l'activation de dipeptidyl peptidase-iv